Lexicon Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-0.65 Insider Own0.60% Shs Outstand183.63M Perf Week4.08%
Market Cap476.29M Forward P/E- EPS next Y-0.63 Insider Trans- Shs Float181.67M Perf Month-7.61%
Income-96.80M PEG- EPS next Q-0.14 Inst Own65.10% Short Float2.21% Perf Quarter13.84%
Sales0.10M P/S4762.89 EPS this Y-14.00% Inst Trans-1.38% Short Ratio2.34 Perf Half Y16.97%
Book/sh0.47 P/B5.43 EPS next Y-5.00% ROA-69.40% Target Price13.00 Perf Year-50.20%
Cash/sh0.33 P/C7.68 EPS next 5Y- ROE-93.60% 52W Range1.31 - 6.33 Perf YTD-35.28%
Dividend- P/FCF- EPS past 5Y13.80% ROI-76.70% 52W High-59.72% Beta1.47
Dividend %- Quick Ratio3.80 Sales past 5Y-67.30% Gross Margin- 52W Low94.66% ATR0.15
Employees87 Current Ratio3.80 Sales Q/Q-85.00% Oper. Margin- RSI (14)46.73 Volatility4.65% 5.41%
OptionableYes Debt/Eq0.00 EPS Q/Q-31.40% Profit Margin- Rel Volume0.29 Prev Close2.42
ShortableYes LT Debt/Eq0.33 EarningsAug 02 AMC Payout- Avg Volume1.72M Price2.55
Recom2.00 SMA20-2.84% SMA50-8.53% SMA200-2.10% Volume502,003 Change5.37%
Aug-12-22Initiated Piper Sandler Overweight $10
Jan-29-21Upgrade JP Morgan Underweight → Neutral $7
Jan-29-21Downgrade Wedbush Outperform → Neutral $2 → $8
Dec-08-20Upgrade Citigroup Neutral → Buy
Nov-18-20Upgrade Gabelli & Co Hold → Buy
Dec-11-19Downgrade Gabelli & Co Buy → Hold
Nov-08-19Downgrade Citigroup Buy → Neutral $3 → $4
Sep-11-19Upgrade Gabelli & Co Hold → Buy $3
Jul-29-19Downgrade Stifel Buy → Hold $10 → $4
Mar-25-19Upgrade Gabelli & Co Sell → Hold
Jul-31-18Reiterated Stifel Buy $24 → $23
Feb-23-18Downgrade Needham Buy → Hold
Feb-14-18Downgrade JP Morgan Neutral → Underweight $10
Mar-01-17Reiterated Wedbush Outperform $33 → $38
Mar-01-17Reiterated H.C. Wainwright Buy $26 → $27
Oct-07-16Initiated H.C. Wainwright Buy $26
Aug-05-16Reiterated Wedbush Outperform $30 → $31
Aug-02-16Initiated Citigroup Buy $21
Mar-02-16Reiterated Wedbush Outperform $26 → $28
Nov-09-15Reiterated Wedbush Outperform $19 → $26
Sep-20-22 08:59AM
Aug-22-22 04:05PM
Aug-05-22 04:59PM
Aug-02-22 04:01PM
Jul-29-22 08:00AM
07:00AM Loading…
Jul-28-22 07:00AM
Jul-27-22 04:01PM
Jun-29-22 04:01PM
Jun-06-22 02:16PM
Jun-01-22 08:00AM
May-31-22 08:00AM
May-11-22 06:35AM
May-05-22 06:00AM
Apr-29-22 08:00AM
08:00AM Loading…
Apr-07-22 08:00AM
Apr-04-22 08:00AM
Apr-02-22 12:15PM
Mar-21-22 08:01AM
Mar-18-22 09:57AM
Mar-17-22 04:14PM
Mar-08-22 04:34AM
Mar-04-22 05:10AM
Mar-03-22 06:21PM
Feb-28-22 04:54PM
Feb-25-22 09:03PM
Jan-13-22 09:00AM
Jan-04-22 04:05PM
10:46AM Loading…
Jan-03-22 10:46AM
Dec-30-21 04:05PM
Nov-15-21 04:30PM
Nov-14-21 08:35AM
Nov-09-21 08:00AM
Nov-03-21 04:02PM
Nov-01-21 11:33AM
Oct-28-21 07:28PM
Oct-06-21 04:28AM
Sep-15-21 08:00AM
Aug-30-21 07:00AM
Aug-23-21 09:45AM
Jul-30-21 08:35AM
Jul-28-21 05:40PM
Jul-22-21 03:03PM
Jun-25-21 08:00AM
May-26-21 04:15PM
May-13-21 04:15PM
May-06-21 08:35PM
May-03-21 06:02AM
Apr-29-21 04:14PM
Apr-19-21 12:30PM
Apr-08-21 04:35PM
Mar-15-21 08:36AM
Mar-10-21 05:55PM
Mar-04-21 04:05PM
Mar-03-21 12:40PM
Mar-02-21 10:02AM
Mar-01-21 10:33AM
Feb-26-21 10:13AM
Feb-11-21 11:05AM
Feb-06-21 06:55AM
Jan-31-21 02:55AM
Jan-29-21 06:56AM
Jan-22-21 10:18AM
Jan-20-21 12:13PM
Jan-15-21 08:31AM
Jan-14-21 08:00AM
Jan-06-21 08:00AM
Jan-04-21 09:40AM
Dec-31-20 08:00AM
Dec-16-20 04:05PM
Dec-12-20 04:03PM
Dec-11-20 06:04PM
Dec-09-20 09:22AM
Nov-16-20 10:02PM
Nov-06-20 07:48AM
Oct-29-20 10:05AM
Oct-27-20 08:00AM
Sep-23-20 06:43PM
Sep-14-20 09:46AM
Sep-08-20 04:05PM
Sep-04-20 08:00AM
Sep-03-20 06:00PM
Aug-24-20 11:35AM
Aug-10-20 11:52AM
Lexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products. Its orally-delivered small molecule drug candidates under development comprise Sotagliflozin that completed Phase III clinical trials for the for the treatment of heart failure and type 1 diabetes; and LX9211, which is in Phase II clinical development for the treatment of neuropathic pain. The company has strategic collaboration and license agreements with Bristol-Myers Squibb Company, and Genentech, Inc. Lexicon Pharmaceuticals, Inc. was incorporated in 1995 and is headquartered in The Woodlands, Texas.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Artal International S.C.A.DirectorAug 01Buy2.5016,173,80040,434,50048,433,261Aug 01 04:15 PM
Invus US Partners LLCDirectorAug 01Buy2.50982,6002,456,5005,303,814Aug 01 04:15 PM
DEBBANE RAYMONDDirectorAug 01Buy2.50982,6002,456,5005,303,814Aug 01 04:13 PM
Swain Judith LDirectorApr 30Option Exercise0.004,024031,030May 02 04:22 PM
SOBECKI CHRISTOPHER JDirectorApr 30Option Exercise0.004,0240149,721May 02 04:18 PM
NIES ALAN SDirectorApr 30Option Exercise0.004,024031,744May 02 04:16 PM
Palantoni FrankDirectorApr 30Option Exercise0.004,024031,030May 02 04:17 PM
LEFKOWITZ ROBERT J MDDirectorApr 30Option Exercise0.004,024031,030May 02 04:15 PM
DEBBANE RAYMONDDirectorApr 30Option Exercise0.004,0240331,545May 02 04:14 PM
Amouyal PhilippeDirectorApr 30Option Exercise0.004,024031,030May 02 04:11 PM
BARKER SAM LDirectorApr 30Option Exercise0.004,024070,315May 02 04:12 PM